MK-4827 in BRCA Ovarian Cancer and Other Advanced Solid Tumours

• Research type

  Research Study

• Full title

  A Phase Ia Study of MK-4827 in Patients With Advanced Solid Tumors and Phase Ib Study in Patients with BRCA Mutant Ovarian Cancer

• Sponsor organisation

  Merck & Co

• Eudract number

  2008-000054-12

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  This study of the novelanti-cancer agent, MK-4827, is designed to identify a dose level suitable forfurther investigation and development. It is divided into two phases. In the first phase, the doses of MK-4827 areincreased and the tolerability to each dose level determined. Once a safe doseof MK-4827 is identified, the number of patients studied at that dose level isincreased to confirm the suitability of the dose. Once a suitable dose forfurther investigation is identified in the first phase of the study, theefficacy of MK-4827 will be studied in a small number of patients who areconsidered to be most likely to benefit from this treatment.

• REC name

  London - Chelsea Research Ethics Committee

• REC reference

  08/H0801/98

• Date of REC Opinion

  29 Oct 2008

• REC opinion

  Further Information Favourable Opinion